Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

HackerRank is a pretty cool place to get better at coding. It’s got tons of challenges that really make you think and figure things out faster. Whether you’re just starting out or you’ve been coding ...

Ever wonder how some folks just seem to breeze through coding challenges and land those awesome tech jobs? A lot of it comes down to practice, and platforms like HackerRank are super helpful for that.

Looking to refresh your stock of “Never Have I Ever” questions? It’s always good to go into a game with a lot of Qs lined up. That way, you don’t have to think of them under pressure, especially if ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...

What's going on with Recursion? Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since the company's management appeared on his ...

Get Even More From Bustle — Sign Up For The Newsletter From hair trends to relationship advice, our daily newsletter has everything you need to sound like a person who’s on TikTok, even if you aren’t.